Posts Tagged ‘pharmaceutical industry’

Unmasking the cost of cancer drug development

Cancer drug R&D spending may be a fraction of the estimate cited by the biopharmaceutical industry.     The average price of anticancer drugs has been rising by about 10 percent annually in recent years, with annual costs for a single drug now routinely running to $100,000 or more. The burden is falling hard on people with cancer. In one study, 34 percent of survivors went into debt (and 9 percent who went into debt … Read More

When cancer drug marketing sneaks into a soap opera plot

Polycythemia vera is an uncommon blood cancer that can be controlled with long-established treatments. So it seemed more than a little suspicious to Vinay Prasad, M.D., M.P.H., when the disease took center stage in an episode of “General Hospital” – the longest running daytime drama on American television. “I felt there had to be some backstory,” Prasad, an OHSU Knight Cancer Institute hematologist-oncologist told listeners of  the public radio program Think Out Loud. “What we found was … Read More

Old cancer drugs, spendy new prices

Prices of older cancer drugs are rising much more steeply than those of newer drugs, according to a study co-authored by an OHSU oncologist.

Sizing up the FDA’s revolving door with industry

When reviewers with the Food and Drug Administration weigh the evidence for a drug company’s experimental treatment, how many are thinking: I may someday work for that company? It’s a difficult question to answer but research by two OHSU physicians provides some of the first hard data.

Targeting leukemia with drug combinations

Targeting leukemia with drug combinations

Cancer researchers have devised a way to rapidly screen combinations of drugs to identify pairs of agents most likely to work synergistically against some of the most difficult to treat forms of leukemia.